These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 24045242

  • 1. Natalizumab (tysabri)-associated progressive multifocal leukoencephalopathy: insights from perfusion magnetic resonance imaging.
    Elster MJ.
    J Comput Assist Tomogr; 2013; 37(5):694-7. PubMed ID: 24045242
    [Abstract] [Full Text] [Related]

  • 2. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
    Yousry TA, Pelletier D, Cadavid D, Gass A, Richert ND, Radue EW, Filippi M.
    Ann Neurol; 2012 Nov; 72(5):779-87. PubMed ID: 23280794
    [Abstract] [Full Text] [Related]

  • 3. Presumptive progressive multifocal leukoencephalopathy in multiple sclerosis after natalizumab therapy.
    Eisele P, Szabo K, Hornberger E, Griebe M, Hennerici MG, Kieseier BC, Gass A.
    J Neuroimaging; 2014 Nov; 24(4):425-8. PubMed ID: 23323645
    [Abstract] [Full Text] [Related]

  • 4. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 5. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP, Richert ND, Killestein J, de Vos M, Sanchez E, Snaebjornsson P, Cadavid D, Barkhof F.
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
    Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, Gold R.
    Mult Scler; 2013 Feb; 19(2):249-51. PubMed ID: 22596228
    [Abstract] [Full Text] [Related]

  • 7. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL, Nicholas JA, Topalli I, Kisanuki YY, Pei W, Morgan-Followell B, Kirsch CF, Racke MK, Pitt D.
    JAMA Neurol; 2013 Mar 01; 70(3):398-402. PubMed ID: 23338729
    [Abstract] [Full Text] [Related]

  • 8. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
    Piola M, Di Palma F, Mascoli N, Binda S, Arnaboldi M, Rezzonico M.
    J Neurol Sci; 2014 May 15; 340(1-2):213-4. PubMed ID: 24642511
    [Abstract] [Full Text] [Related]

  • 9. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS.
    Vennegoor A, Wattjes MP, van Munster ET, Kriekaart RL, van Oosten BW, Barkhof F, Killestein J, Polman CH.
    Neurology; 2011 Feb 08; 76(6):574-6. PubMed ID: 21300973
    [No Abstract] [Full Text] [Related]

  • 10. Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?
    Maillart E, Louapre C, Lubetzki C, Papeix C.
    Mult Scler; 2014 Apr 08; 20(4):505-9. PubMed ID: 24367037
    [Abstract] [Full Text] [Related]

  • 11. Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI.
    Wattjes MP, Barkhof F.
    Curr Opin Neurol; 2014 Jun 08; 27(3):260-70. PubMed ID: 24739400
    [Abstract] [Full Text] [Related]

  • 12. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
    Wenning W, Haghikia A, Laubenberger J, Clifford DB, Behrens PF, Chan A, Gold R.
    N Engl J Med; 2009 Sep 10; 361(11):1075-80. PubMed ID: 19741228
    [Abstract] [Full Text] [Related]

  • 13. Natalizumab: bench to bedside and beyond.
    Rudick R, Polman C, Clifford D, Miller D, Steinman L.
    JAMA Neurol; 2013 Feb 10; 70(2):172-82. PubMed ID: 23128399
    [Abstract] [Full Text] [Related]

  • 14. Transient punctuate enhancing lesions preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Taieb G, Renard D, Thouvenot E, Servillo G, Castelnovo G.
    J Neurol Sci; 2014 Nov 15; 346(1-2):364-5. PubMed ID: 25241939
    [No Abstract] [Full Text] [Related]

  • 15. Immunological and clinical consequences of treating a patient with natalizumab.
    Schwab N, Höhn KG, Schneider-Hohendorf T, Metz I, Stenner MP, Jilek S, Du Pasquier RA, Gold R, Meuth SG, Ransohoff RM, Brück W, Wiendl H.
    Mult Scler; 2012 Mar 15; 18(3):335-44. PubMed ID: 21908480
    [Abstract] [Full Text] [Related]

  • 16. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M, Päivärinta M, Sonninen P, Parkkola R, Vuorinen T, Erälinna JP.
    Duodecim; 2013 Mar 15; 129(7):765-70. PubMed ID: 23720945
    [Abstract] [Full Text] [Related]

  • 17. Natalizumab-induced progressive multifocal leukoencephalopathy.
    Thaker AA, Schmitt SE, Pollard JR, Dubroff JG.
    Clin Nucl Med; 2014 Jul 15; 39(7):e365-6. PubMed ID: 24152618
    [Abstract] [Full Text] [Related]

  • 18. [Progressive multifocal leukoencephalopathy and natalizumab-related immune reconstitution inflammatory syndrome: the advantage of MRI].
    Gibelin N, Daelman L, Goulipian S, Wynckel A, Chaunu MP, Tourbah A.
    Rev Neurol (Paris); 2014 Jan 15; 170(1):48-50. PubMed ID: 24139244
    [No Abstract] [Full Text] [Related]

  • 19. The earlier, the smaller, the better for natalizumab-associated PML: in MRI vigilance veritas?
    Phan-Ba R, Belachew S, Outteryck O, Moonen G, Sindic C, Vokaer M, Vermersch P.
    Neurology; 2012 Sep 04; 79(10):1067-9. PubMed ID: 22914844
    [No Abstract] [Full Text] [Related]

  • 20. Treating multiple sclerosis with natalizumab.
    Iaffaldano P, Lucchese G, Trojano M.
    Expert Rev Neurother; 2011 Dec 04; 11(12):1683-92. PubMed ID: 22091593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.